OmniAb (OABI) Gross Margin (2024 - 2026)
OmniAb (OABI) reported Gross Margin of 99.9% for Q1 2026, down 3.0% year-over-year from 102.99% in Q1 2025, and little changed on a QoQ basis from 99.89% in Q4 2025.
OmniAb (OABI) has 3 years of Gross Margin data on file, last reported at 99.9% in Q1 2026.
- Quarterly Gross Margin fell 3.0% year-over-year to 99.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.91% (down 108.0% YoY) and the FY2025 annual result came in at 98.38%, down 162.0% from the prior year.
- Gross Margin steadied at 99.9% in Q1 2026 per OABI's latest filing, from 99.89% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q2 2024 and bottomed at 93.28% in Q2 2025.
- The 3-year median for Gross Margin is 99.91% (2025), against an average of 98.96%.
- The widest annual swing landed in 2025, when Gross Margin slumped 672 bps; it then slipped 3 bps in 2026.
- Tracing OABI's Gross Margin over 3 years: stood at 100.0% in 2024, then dropped by 0 bps to 99.89% in 2025, then climbed by 0 bps to 99.9% in 2026.
- Per Business Quant, the three latest OABI Gross Margin figures stand at 99.9% (Q1 2026), 99.89% (Q4 2025), and 98.7% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 99.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.90% |
| Dec 31, 2025 | 99.89% |
| Sep 30, 2025 | 98.70% |
| Jun 30, 2025 | 93.28% |
| Mar 31, 2025 | 99.93% |
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 100.00% |
| Jun 30, 2024 | 100.00% |